Thyroid Cancer

1. Overview

Thyroid cancer is the most common endocrine malignancy and represents approximately 1-2% of all human cancers worldwide. [1] The incidence has been rising dramatically over the past three decades, partly due to improved detection of small, subclinical papillary thyroid microcarcinomas through incidental imaging and increased use of ultrasound surveillance. [2] Despite this rising incidence, mortality rates have remained stable, suggesting that much of the increase represents detection of low-risk, indolent disease.

The vast majority (> 90%) of thyroid cancers are differentiated thyroid cancers (DTC), comprising papillary and follicular subtypes, which originate from thyroid follicular epithelial cells and retain the ability to concentrate iodine and respond to thyroid-stimulating hormone (TSH). These cancers generally have an excellent prognosis, with 10-year survival rates exceeding 90-95%. [3]

Medullary thyroid carcinoma (MTC) arises from parafollicular C-cells and accounts for approximately 3-5% of thyroid malignancies. It secretes calcitonin and is associated with hereditary cancer syndromes in 25-30% of cases. [4] Anaplastic thyroid carcinoma (ATC) is a rare (less than 2%) but highly aggressive undifferentiated cancer with median survival measured in months rather than years. [5]

The key clinical message is that thyroid cancer is highly heterogeneous: most patients with differentiated disease will be cured with appropriate treatment, but a subset of patients with aggressive variants, extensive local invasion, or distant metastases require intensive multimodal therapy and carry a guarded prognosis.

---

2. Epidemiology

Incidence and Prevalence

Demographics

Age Distribution:

• Papillary carcinoma: Typically presents in young to middle-aged adults (30-50 years), though can occur at any age
• Follicular carcinoma: Older demographic (40-60 years)
• Medullary carcinoma: Sporadic forms present in 40s-50s; hereditary MEN2 forms present in childhood or young adulthood
• Anaplastic carcinoma: Elderly patients, peak incidence > 65 years

Sex Predilection: Women are affected 3 times more frequently than men across all histological subtypes. However, male sex is paradoxically associated with more aggressive disease and worse prognosis. [6]

Geographic Variation: Follicular carcinoma is more common in iodine-deficient regions (mountainous areas, inland regions away from the sea). Following iodine supplementation programs, the relative proportion shifts toward papillary carcinoma. [7]

Risk Factors

Ionizing Radiation: The strongest established environmental risk factor. Childhood exposure to external beam radiation (for benign conditions, malignancies, or accidental exposure) increases risk 5-10 fold, with peak incidence 15-25 years post-exposure. [8] The Chernobyl nuclear accident (1986) led to a dramatic increase in pediatric papillary thyroid cancers in Belarus, Ukraine, and Russia. [9] Internal radiation from radioactive iodine (I-131) fallout is particularly thyrotrophic.

Family History and Genetic Syndromes:

• Familial non-medullary thyroid cancer: 5-10% of papillary and follicular cancers exhibit familial clustering without a defined syndrome
• MEN2A and MEN2B: Germline RET proto-oncogene mutations cause medullary thyroid carcinoma in virtually 100% of cases [4]
• Familial adenomatous polyposis (FAP): Associated with cribriform-morular variant of papillary thyroid cancer
• Cowden syndrome (PTEN hamartoma syndrome): Increased risk of follicular thyroid cancer
• Carney complex: Associated with follicular adenomas and carcinomas

Other Factors:

• Pre-existing benign thyroid disease (multinodular goitre, thyroid adenoma) - weak association
• Obesity - emerging evidence suggests modest increased risk [10]
• Hormonal factors - higher incidence in women, potential role of estrogen

---

3. Aetiology and Pathophysiology

Molecular Genetics

The development of thyroid cancer involves stepwise accumulation of genetic alterations that drive uncontrolled cellular proliferation, invasion, and metastasis.

Papillary Thyroid Carcinoma (PTC)

BRAF V600E Mutation (40-45% of PTCs): [11]

• Point mutation in the BRAF gene encoding a serine/threonine kinase in the MAPK signaling pathway
• Leads to constitutive activation of MAPK pathway, promoting cell proliferation
• Associated with more aggressive tumor behavior, extrathyroidal extension, lymph node metastases, and reduced radioiodine avidity
• More common in classic and tall-cell variants

RET/PTC Rearrangements (10-20% of PTCs): [12]

• Chromosomal rearrangements fusing the RET tyrosine kinase domain with various partner genes
• Creates constitutively active chimeric oncoproteins
• RET/PTC1 and RET/PTC3 are most common
• Strongly associated with radiation-induced papillary cancers (60-80% of post-Chernobyl pediatric cases)

RAS Mutations (10-15% of PTCs):

• Point mutations in NRAS, HRAS, or KRAS
• Associated with follicular variant of papillary carcinoma
• Overlapping molecular signature with follicular carcinoma

Follicular Thyroid Carcinoma (FTC)

RAS Mutations (40-50% of FTCs):

• Most common genetic alteration in FTC
• Activates both MAPK and PI3K-AKT signaling pathways

PAX8-PPARγ Rearrangement (30-35% of FTCs):

• Fusion of PAX8 (thyroid transcription factor) with PPARγ (nuclear receptor)
• More common in younger patients and conventional follicular carcinomas
• Generally associated with favorable prognosis

PIK3CA Mutations and PTEN Loss:

• Activate PI3K-AKT-mTOR pathway
• Associated with more aggressive follicular cancers

Medullary Thyroid Carcinoma (MTC)

RET Proto-oncogene Mutations: [4]

• Hereditary MTC (25-30%): Germline RET mutations transmitted in autosomal dominant pattern
  • "MEN2A: Codon 634 mutations most common (> 80%)"
  • "MEN2B: Codon 918 mutations (M918T) - most aggressive"
  • "Familial MTC (FMTC): RET mutations without other MEN2 features"
• Sporadic MTC (70-75%): Somatic RET mutations in ~50% of cases (M918T most common)

Anaplastic Thyroid Carcinoma (ATC)

ATC is thought to arise either de novo or through dedifferentiation of pre-existing differentiated thyroid cancer. Molecular profile shows:

• TP53 mutations (60-80%) - hallmark of ATC [5]
• BRAF V600E mutations (20-40%)
• RAS mutations (20-30%)
• PIK3CA mutations
• Loss of tumor suppressors (PTEN, p53)
• Telomerase promoter (TERT) mutations - associated with progression from DTC to ATC

Cellular Pathophysiology

Follicular Cell-Derived Cancers (PTC, FTC, ATC): Originate from thyroid follicular epithelial cells responsible for thyroid hormone synthesis. These tumors:

• Retain variable TSH responsiveness (more in DTC, lost in ATC)
• Express thyroglobulin (used as tumor marker)
• Retain sodium-iodide symporter (NIS) expression in well-differentiated forms, enabling radioiodine therapy

Parafollicular C-Cell Derived Cancer (MTC): Arises from neuroendocrine C-cells that produce calcitonin. These tumors:

• Secrete calcitonin and carcinoembryonic antigen (CEA) - used as tumor markers
• Do NOT concentrate radioiodine (lack NIS expression)
• May secrete other peptides (ACTH, serotonin) causing paraneoplastic syndromes

Routes of Spread

Papillary Carcinoma: Predominantly lymphatic spread

• Early involvement of central compartment (level VI) lymph nodes
• Lateral neck nodes (levels II-V) in 20-50%
• Intraglandular lymphatic spread common - explains multifocality
• Distant metastases (lungs, bones) in less than 5% at presentation

Follicular Carcinoma: Predominantly hematogenous spread

• Vascular invasion through tumor capsule defines malignancy
• Distant metastases to bones (40-60%) and lungs (25-50%)
• Lymph node metastases uncommon (less than 10%)

Medullary Carcinoma: Both lymphatic and hematogenous

• Early cervical lymph node metastases (> 50% at presentation)
• Distant metastases to liver, lungs, bones

Anaplastic Carcinoma: Aggressive local invasion

• Rapid infiltration of surrounding structures (trachea, esophagus, recurrent laryngeal nerve, carotid sheath)
• Early distant metastases (lungs, bones, brain)

---

4. Clinical Presentation

Symptoms

Asymptomatic Thyroid Nodule (Most Common Presentation): The majority of thyroid cancers, particularly small papillary carcinomas, are discovered incidentally as asymptomatic thyroid nodules detected on imaging performed for other indications, or found during routine physical examination. Patients are typically euthyroid.

Local Symptoms:

• Palpable neck mass: Painless, firm nodule that moves with swallowing (attached to thyroid)
• Neck discomfort: Vague sensation of fullness or pressure
• Dysphagia: Difficulty swallowing, suggests posterior extension or large goiter
• Hoarseness: Suggests recurrent laryngeal nerve (RLN) involvement - RED FLAG
• Stridor or dyspnea: Tracheal compression from large or invasive tumor - URGENT
• Cough or hemoptysis: Tracheal invasion (particularly anaplastic carcinoma)

Metastatic Symptoms:

• Pathological fracture: Bone metastases (follicular > papillary)
• Dyspnea: Lung metastases ("snowstorm" or "cannonball" pattern on chest X-ray)
• Neurological symptoms: Brain metastases (rare)

Systemic Symptoms:

• Diarrhea and flushing: Medullary carcinoma secreting calcitonin or other peptides
• Cushing syndrome: Ectopic ACTH secretion from MTC (rare)
• Constitutional symptoms: Weight loss, fatigue in advanced/metastatic disease

Signs

Thyroid Examination:

• Nodule characteristics:
  • Hard, irregular, fixed nodule raises suspicion for malignancy
  • Benign nodules tend to be soft, smooth, mobile
  • However, clinical examination alone has limited sensitivity/specificity
• Size: Larger nodules (> 4 cm) have higher false-negative FNA rates
• Mobility: Fixation to surrounding structures suggests extrathyroidal extension (T4 disease)
• Gland symmetry: Dominant nodule within asymmetric gland

Cervical Lymphadenopathy:

• Central compartment (level VI): Paratracheal, pretracheal, prelaryngeal nodes
• Lateral neck (levels II-V): Suggests more extensive disease
• Characteristics: Firm, non-tender, may be matted
• Papillary carcinoma: Lymph nodes may have cystic changes on ultrasound

Vocal Cord Assessment:

• Pre-operative laryngoscopy: Essential in all patients undergoing thyroidectomy to document baseline vocal cord function
• Unilateral cord palsy: Breathy, hoarse voice; suggests RLN invasion
• Bilateral cord palsy: Stridor, airway compromise; requires urgent airway management

Signs of Advanced/Metastatic Disease:

• Pemberton's sign: Facial plethora and venous congestion when arms raised above head (retrosternal goiter causing SVC obstruction)
• Horner syndrome: Cervical sympathetic chain involvement
• Pulsatile bone metastases: Hypervascular follicular cancer metastases

---

5. Differential Diagnosis

The primary clinical challenge is distinguishing malignant thyroid nodules from benign ones, as benign nodules are extremely common (palpable in 4-7% of adults, detected on ultrasound in 20-76%).

Benign Thyroid Conditions

1. Benign Follicular Adenoma:

• Most common benign thyroid neoplasm
• Clinically and cytologically indistinguishable from follicular carcinoma (requires histology showing intact capsule without vascular invasion)
• Thy3 category on FNA cytology

2. Multinodular Goitre:

• Multiple nodules of varying size
• May have dominant nodule requiring FNA
• Endemic in iodine-deficient regions

3. Hashimoto's Thyroiditis:

• Diffuse thyroid enlargement, may have pseudonodules
• Associated with hypothyroidism, positive anti-thyroid antibodies
• Small increased risk of thyroid lymphoma

4. Simple/Colloid Cyst:

• Fluid-filled, often benign on aspiration
• U2 on ultrasound (anechoic, well-defined)

Malignant Differential

5. Primary Thyroid Lymphoma:

• Usually non-Hodgkin B-cell lymphoma (MALT or diffuse large B-cell)
• Associated with longstanding Hashimoto's thyroiditis in 60-80%
• Presents as rapidly enlarging, firm thyroid mass in elderly patient
• May cause compressive symptoms
• Diagnosis requires core biopsy (not FNA)

6. Metastases to Thyroid:

• Rare (less than 5% of thyroid malignancies)
• Primary sites: Renal cell carcinoma (most common), lung, breast, melanoma
• Usually in patients with known primary malignancy

Key Distinguishing Features

---

6. Investigations

The diagnostic pathway for suspected thyroid cancer follows a structured approach integrating clinical assessment, biochemistry, imaging, and tissue sampling.

Thyroid Function Tests

TSH, Free T4, Free T3:

• Most thyroid cancers present in euthyroid patients
• TSH level helps exclude functional autonomy
• Suppressed TSH: Suggests hyperfunctioning "hot" nodule (rarely malignant, less than 1%)
• Elevated TSH: Slightly increased malignancy risk (TSH is growth factor for follicular cells) [13]

Tumor Markers

Thyroglobulin (Tg):

• NOT useful for initial diagnosis (elevated in many benign conditions: goiter, thyroiditis, adenomas)
• Essential for post-operative surveillance after total thyroidectomy
  • Should be undetectable (less than 1 ng/mL) after total thyroidectomy + radioiodine ablation
  • Rising Tg indicates recurrence/persistent disease
• Must measure with anti-Tg antibodies (interfere with assay in 15-20%)

Calcitonin:

• Specific for medullary thyroid carcinoma (secreted by parafollicular C-cells)
• Routine screening controversial but recommended in:
  • Family history of MTC or MEN2
  • Thy3/Thy4 nodules
  • Large/bilateral thyroid nodules
• Basal calcitonin > 100 pg/mL: Highly suspicious for MTC [4]
• Stimulated calcitonin testing (pentagastrin or calcium): Increased sensitivity in early disease

Carcinoembryonic Antigen (CEA):

• Co-secreted with calcitonin in MTC
• Useful for monitoring MTC recurrence
• Elevated in other malignancies (less specific than calcitonin)

Thyroid Ultrasound

First-line imaging modality for thyroid nodule characterization. Multiple risk stratification systems exist (ACR TI-RADS, EU-TIRADS, BTA U-classification).

BTA U-Classification System: [14]

High-Risk Ultrasound Features:

• Hypoechogenicity: Darker than surrounding thyroid tissue
• Microcalcifications: Punctate echogenic foci less than 1mm (psammoma bodies in papillary carcinoma)
• Irregular/infiltrative margins: Loss of smooth capsule
• Taller-than-wide shape: Anteroposterior diameter > transverse diameter on transverse view
• Abnormal vascularity: Chaotic internal vascularity
• Extrathyroidal extension: Invasion into strap muscles or adjacent structures

Cervical Lymph Node Assessment: Ultrasound evaluation of central (level VI) and lateral (levels II-V) neck compartments is essential:

• Suspicious features: Loss of fatty hilum, round shape (S/L ratio less than 2), cystic change, microcalcifications, peripheral vascularity

Fine Needle Aspiration (FNA) Cytology

Indications for FNA (ATA Guidelines): [3]

• All nodules ≥1 cm with suspicious ultrasound features (U3-U5)
• Nodules less than 1 cm if:
  • High-risk patient (radiation exposure, family history)
  • Suspicious cervical lymphadenopathy
  • Extrathyroidal extension
  • High-risk ultrasound features

Technique:

• Ultrasound-guided FNA (preferred over palpation-guided - higher accuracy)
• Usually 25-27 gauge needle
• Multiple passes (typically 2-4) for adequate cellularity
• On-site cytology assessment (if available) improves adequacy

Bethesda Classification System (Thy Classification in UK):

The "Follicular Dilemma" (Thy3f): Cytology CANNOT distinguish follicular adenoma from follicular carcinoma because the defining feature is capsular or vascular invasion, which can only be assessed on surgical histopathology. Therefore, Thy3f nodules require diagnostic hemithyroidectomy with intraoperative frozen section or definitive histology.

FNA Limitations:

• Non-diagnostic rate: 10-20% (improved with ultrasound guidance)
• False-negative rate: 1-5%
• Cannot diagnose follicular carcinoma
• Cannot diagnose minimally invasive cancers

Molecular Testing

Increasingly used for indeterminate FNA samples (Thy3a/Thy3f) to refine malignancy risk and guide surgical decision-making.

Gene Mutation Panels:

• Test for BRAF, RAS, RET/PTC, PAX8-PPARγ
• High specificity (BRAF V600E: 99% specific for PTC)
• "Rule-in" malignancy if positive

Gene Expression Classifiers (e.g., Afirma):

• mRNA expression profiling
• High sensitivity (> 90%)
• "Rule-out" malignancy if negative - avoid surgery

Cross-Sectional Imaging

CT or MRI Neck: Indicated for:

• Large goiters with retrosternal extension (CT preferred)
• Suspected extrathyroidal extension or tracheal invasion
• Extensive lymphadenopathy
• Pre-operative planning for complex cases

Contraindication: Iodinated contrast should be avoided if radioiodine therapy planned (iodine load delays RAI therapy for 6-8 weeks)

Chest X-Ray:

• Baseline assessment for lung metastases in all DTC patients
• "Snowstorm" or "cannonball" metastases if present

FDG PET-CT:

• Limited role in initial diagnosis
• Useful for:
  • Recurrent disease localization when Tg elevated but radioiodine scan negative (dedifferentiated cancers)
  • Staging aggressive variants (poorly differentiated, anaplastic)
  • Medullary carcinoma staging

Staging Investigations (Post-Diagnosis)

Radioiodine Whole Body Scan (I-123 or Low-Dose I-131):

• Performed after total thyroidectomy in intermediate/high-risk DTC
• Detects residual thyroid tissue and distant metastases
• Requires TSH stimulation (endogenous after levothyroxine withdrawal or exogenous rhTSH)

---

7. Classification and Staging

Histological Classification (WHO)

1. Papillary Thyroid Carcinoma (80-85%)

Subtypes with prognostic implications:

• Classic papillary: Most common
• Follicular variant: Encapsulated or infiltrative; NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features) is now recognized as indolent
• Tall cell variant (10-15% of PTC): Cells twice as tall as wide; more aggressive, older patients, higher recurrence
• Columnar cell variant: Rare, aggressive
• Diffuse sclerosing variant: Young patients, diffuse involvement, extensive lymphatic spread

Histological Features:

• Orphan Annie nuclei: Ground-glass, optically clear nuclei (due to chromatin margination)
• Nuclear grooves and pseudoinclusions
• Psammoma bodies: Concentric calcifications (laminated calcium deposits)

2. Follicular Thyroid Carcinoma (10-15%)

• Minimally invasive: Capsular invasion only; excellent prognosis (> 95% 10-year survival)
• Widely invasive: Extensive vascular invasion; higher metastatic risk, worse prognosis

Histological Features:

• Follicular architecture (microfollicular, normofollicular, trabecular patterns)
• Capsular invasion: Penetration through tumor capsule
• Vascular invasion: Tumor within blood vessels within/outside capsule

3. Hürthle Cell (Oncocytic) Carcinoma

• Variant of follicular carcinoma (some classify separately)
• Cells packed with mitochondria (eosinophilic, granular cytoplasm)
• Generally more aggressive than conventional follicular carcinoma
• Poorer radioiodine uptake

4. Medullary Thyroid Carcinoma (3-5%)

• Sporadic (70-75%): Unilateral, older age
• Hereditary (25-30%): MEN2A, MEN2B, Familial MTC
  • Often bilateral and multifocal
  • Associated C-cell hyperplasia

Histological Features:

• Sheets or nests of polygonal/spindle cells
• Amyloid deposition (from calcitonin aggregation) - Congo red positive
• Immunostains: Calcitonin+, CEA+, chromogranin+, TTF-1-

5. Anaplastic (Undifferentiated) Thyroid Carcinoma (less than 2%)

• Most aggressive thyroid malignancy
• Often arises from dedifferentiation of existing DTC (40-50% have coexisting DTC)

Histological Features:

• Pleomorphic, highly atypical cells
• Spindle cells, giant cells, epithelioid cells
• High mitotic activity, necrosis
• Infiltrative growth

TNM Staging (AJCC 8th Edition)

Thyroid cancer staging is age-dependent because age is the strongest prognostic factor in DTC.

T - Primary Tumor:

• T1: ≤2 cm, limited to thyroid
  • T1 a: ≤1 cm
  • T1 b: > 1 to ≤2 cm
• T2: > 2 to ≤4 cm, limited to thyroid
• T3: > 4 cm limited to thyroid OR any size with gross extrathyroidal extension into strap muscles (T3a) or minimal extrathyroidal extension (T3b)
• T4:
  • T4 a: Invasion into subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
  • T4 b: Invasion into prevertebral fascia, mediastinal vessels, or encasement of carotid artery

N - Regional Lymph Nodes:

• N0: No regional lymph node metastases
• N1: Regional lymph node metastases
  • N1 a: Metastases in central compartment (level VI)
  • N1 b: Metastases in lateral neck (levels I-V) or superior mediastinal (level VII)

M - Distant Metastases:

• M0: No distant metastases
• M1: Distant metastases (lungs, bones, liver, brain)

Stage Grouping for Papillary/Follicular Carcinoma:

Patients less than 55 years:

• Stage I: Any T, Any N, M0
• Stage II: Any T, Any N, M1

Patients ≥55 years:

• Stage I: T1, N0/NX, M0
• Stage II: T1, N1, M0 OR T2, N0/N1, M0
• Stage III: T3, any N, M0 OR T4a, any N, M0
• Stage IVA: T4b, any N, M0
• Stage IVB: Any T, any N, M1

Key Point: Patients less than 55 years cannot have stage III or IV disease unless they have distant metastases (M1), reflecting the excellent prognosis in younger patients.

Medullary and Anaplastic Carcinoma Staging:

• Uses same TNM system but different stage groupings (age NOT a factor)
• Anaplastic carcinoma is always considered Stage IV (IVA, IVB, or IVC depending on extent)

ATA Risk Stratification

The American Thyroid Association risk stratification system predicts recurrence risk and guides post-operative management: [3]

Low Risk (5-10% recurrence):

• Papillary carcinoma with:
  • No local/distant metastases
  • Complete tumor resection
  • No tumor invasion of locoregional tissues
  • No aggressive histology (tall cell, columnar, hobnail)
  • No vascular invasion
  • No RAI uptake outside thyroid bed (if RAI given)
• Intrathyroidal, well-differentiated follicular carcinoma
• Papillary microcarcinoma (less than 1 cm) - may consider active surveillance in selected patients

Intermediate Risk (20-40% recurrence):

• Microscopic invasion into perithyroidal soft tissues
• RAI uptake in neck outside thyroid bed
• Aggressive histology or vascular invasion
• Papillary carcinoma with N1 (≤5 involved lymph nodes, all less than 3 cm)
• Multifocal papillary microcarcinoma with extrathyroidal extension

High Risk (> 50% recurrence):

• Macroscopic tumor invasion
• Incomplete tumor resection
• Distant metastases (M1)
• Postoperative Tg suggesting distant metastases
• Papillary carcinoma with N1 (> 5 involved nodes or any node ≥3 cm)
• Follicular carcinoma with extensive vascular invasion

---

8. Management

Management of thyroid cancer is risk-stratified and multidisciplinary, involving endocrinology, surgery, nuclear medicine, and oncology.

Diagnostic and Therapeutic Surgery

Surgical Options:

1. Diagnostic Hemithyroidectomy (Lobectomy): Indications:

• Thy3a/Thy3f (indeterminate cytology) - diagnostic procedure
• Small (less than 1-2 cm), low-risk, unifocal intrathyroidal papillary carcinoma in low-risk patients [3]
• Follicular carcinoma less than 4 cm without concerning features

Advantages:

• Avoids lifelong levothyroxine
• Preserves parathyroid function
• Lower surgical risk

2. Total Thyroidectomy: Indications:

• Papillary or follicular carcinoma > 4 cm
• Bilateral thyroid disease
• Extrathyroidal extension
• Lymph node metastases
• Distant metastases
• Prior radiation exposure
• Family history or high-risk features
• Patient preference for RAI treatment

Advantages:

• Enables radioiodine therapy
• Facilitates thyroglobulin monitoring (should be undetectable)
• Removes all potential disease
• May reduce recurrence in bilateral/multifocal disease

3. Completion Thyroidectomy: Performed when initial hemithyroidectomy shows:

• Follicular carcinoma with vascular invasion
• Papillary carcinoma with high-risk features
• Tumor > 4 cm
• Not indicated for minimally invasive follicular carcinoma less than 2 cm

4. Lymph Node Dissection:

Central Neck Dissection (Level VI): [15]

• Therapeutic: Indicated when central lymph nodes clinically/radiologically positive
• Prophylactic: Controversial; considered in T3/T4 tumors or clinically N1b disease (ATA recommendation: may consider in cN0 papillary cancer)
• Structures at risk: Recurrent laryngeal nerves, parathyroid glands

Lateral Neck Dissection (Levels II-V):

• Indicated when lateral lymph nodes involved (N1b)
• "Berry picking" (selective node removal) is inadequate - formal compartmental dissection required
• Modified radical neck dissection (preserving sternocleidomastoid, internal jugular vein, spinal accessory nerve)

Surgical Complications:

Bilateral RLN injury → Vocal cords in paramedian position → Airway obstruction → Emergency tracheostomy

Radioactive Iodine (RAI) Therapy

Mechanism: Differentiated thyroid cancer cells retain expression of sodium-iodide symporter (NIS) and concentrate iodine. Oral I-131 (radioiodine) is selectively taken up by thyroid tissue and emits beta particles, causing targeted cell death.

Indications: [3]

• Remnant ablation: Destroy residual normal thyroid tissue post-total thyroidectomy (improves Tg monitoring specificity, may reduce recurrence)
• Adjuvant treatment: Treat suspected microscopic residual disease in intermediate/high-risk patients
• Known disease treatment: Treat macroscopic locoregional or distant metastases

ATA Recommendations:

• Low risk: RAI NOT routinely recommended (unifocal papillary less than 1-2 cm, no ETE, N0, M0)
• Intermediate risk: Consider RAI (individualized decision)
• High risk: RAI recommended

Preparation:

• Requires elevated TSH (> 30 mU/L) to stimulate iodine uptake:
  • "Thyroid hormone withdrawal (THW): Stop levothyroxine 4-6 weeks, causes hypothyroidism symptoms"
  • "Recombinant human TSH (rhTSH): IM injections on days 1-2, RAI on day 3; patient remains euthyroid; equally effective"
• Low-iodine diet: 1-2 weeks pre-RAI to deplete body iodine stores and increase avidity

Dosing:

• Low-dose (30-100 mCi/1.1-3.7 GBq): Remnant ablation in low-intermediate risk
• High-dose (100-200 mCi/3.7-7.4 GBq): Known residual/metastatic disease

Post-RAI Isolation:

• Patient is radioactive (gamma and beta emission)
• Isolation period depends on dose and local regulations (typically 24-72 hours)
• Avoid close contact with pregnant women and children

Side Effects:

• Acute: Sialadenitis (30%), nausea, neck pain/edema
• Subacute: Taste changes, dry mouth, lacrimal duct obstruction
• Long-term: Increased risk of second malignancies (leukemia, salivary cancers) with cumulative doses > 600 mCi; gonadal dysfunction/infertility (transient in most, advise delay pregnancy 6-12 months)

Contraindications:

• Pregnancy (absolute)
• Breastfeeding (absolute)

RAI-Refractory Disease:

• Lesions that no longer concentrate radioiodine (loss of NIS expression)
• Often dedifferentiated cancers with poor prognosis
• Requires alternative therapies (targeted therapy, EBRT)

TSH Suppression Therapy

Rationale: TSH stimulates growth of follicular cells and differentiated thyroid cancer cells via TSH receptor. Suppressing TSH with supraphysiologic levothyroxine deprives cancer cells of growth signal. [16]

Target TSH Levels (ATA Guidelines): [3]

Evidence: Multiple retrospective studies and meta-analyses show reduced recurrence and mortality in high-risk DTC with TSH suppression less than 0.1 mU/L. [16] However, no high-quality RCTs exist.

Risks of Over-Suppression:

• Subclinical hyperthyroidism → atrial fibrillation (especially elderly) [17]
• Reduced bone mineral density → osteoporosis/fractures (postmenopausal women) [18]
• Requires careful risk-benefit assessment and monitoring

Monitoring:

• TSH and free T4 every 6-12 months
• Adjust levothyroxine dose to maintain target
• ECG if elderly or cardiac risk factors
• Bone densitometry (DEXA) in postmenopausal women on long-term suppression

Management of Specific Subtypes

Medullary Thyroid Carcinoma:

• Surgery is primary treatment: Total thyroidectomy + central neck dissection (even if cN0, due to high rate of microscopic nodal disease) [4]
• NO role for radioiodine (C-cells do not express NIS)
• Pre-operative assessment:
  • Screen for pheochromocytoma (24-hour urinary metanephrines) in ALL patients → treat pheo FIRST to avoid hypertensive crisis
  • Screen for hyperparathyroidism (calcium, PTH) if MEN2A suspected
• Genetic testing: Germline RET mutation testing in ALL MTC patients (identify hereditary cases)
  • If positive → screen family members; offer prophylactic thyroidectomy to mutation carriers (timing based on codon mutation aggressiveness)
• Post-operative monitoring: Serum calcitonin and CEA (tumor markers)
  • Undetectable calcitonin post-op indicates cure
  • Rising calcitonin indicates recurrence
• Systemic therapy for advanced disease:
  • "Tyrosine kinase inhibitors: Vandetanib, cabozantinib (target RET/VEGFR/EGFR) approved for progressive MTC"
  • "Selpercatinib, pralsetinib: Selective RET inhibitors (newer, better tolerated)"

Anaplastic Thyroid Carcinoma:

• Dismal prognosis: Median survival 3-5 months [5]
• Often presents with airway compromise requiring urgent tracheostomy
• Multidisciplinary approach:
  • "Surgery: Role limited; only if R0 resection possible (rare). Debulking for airway/palliation."
  • "External beam radiotherapy (EBRT): Mainstay for local control (intensity-modulated RT, 50-70 Gy)"
  • "Chemotherapy: Doxorubicin, cisplatin, paclitaxel (modest benefit)"
  • "Targeted therapy: "
    • BRAF V600E mutation present in ~40% → Dabrafenib + trametinib (BRAF/MEK inhibitors) show promising responses [19]
    • Lenvatinib (multi-kinase inhibitor)
• Palliative care: Early involvement for symptom management and goals of care discussions

Poorly Differentiated Thyroid Carcinoma (PDTC):

• Intermediate behavior between DTC and ATC
• Aggressive but retains some differentiation
• Treatment: Total thyroidectomy, consider RAI (if avid), consider EBRT for high-risk disease
• Targeted therapy if RAI-refractory

Follow-Up and Surveillance

Low-Risk DTC (Post-Lobectomy or Total Thyroidectomy):

• Clinical examination: 6-12 months initially, then annually
• Neck ultrasound: 6-12 months, then annually for 5 years
• If total thyroidectomy: Thyroglobulin every 6-12 months (should be less than 1 ng/mL on levothyroxine)
• Ongoing levothyroxine replacement (dose to maintain target TSH)

Intermediate/High-Risk DTC:

• More frequent monitoring initially (3-6 monthly)
• Stimulated Tg testing (rhTSH stimulation) at 6-12 months post-RAI:
  • "Tg less than 1 ng/mL: Excellent response"
  • "Tg 1-10 ng/mL: Indeterminate"
  • "Tg > 10 ng/mL: Biochemical incomplete response → further imaging"
• Neck ultrasound every 6 months for 2 years, then annually
• Consider diagnostic I-131 whole-body scan at 1 year if high-risk
• Cross-sectional imaging (CT/MRI) if rising Tg or suspicious findings

Response to Therapy Classification (ATA Dynamic Risk Stratification): [3]

• Excellent response: Undetectable Tg, negative imaging → very low recurrence risk (less than 1%)
• Biochemical incomplete response: Elevated Tg, negative imaging → 20% develop structural disease
• Structural incomplete response: Persistent/recurrent locoregional or distant disease on imaging → requires additional treatment
• Indeterminate response: Non-specific findings → continued surveillance

---

9. Prognosis and Outcomes

Prognosis in thyroid cancer is highly variable and depends on histological subtype, stage, age, and completeness of resection.

Differentiated Thyroid Cancer (Papillary and Follicular)

Overall Excellent Prognosis:

• 10-year overall survival: > 90-95% [3]
• 20-year overall survival: ~85%

Prognostic Factors:

Favorable:

• Age less than 55 years (strongest prognostic factor)
• Female sex
• Small tumor size (less than 2 cm)
• Intrathyroidal disease (no extrathyroidal extension)
• Classic papillary or minimally invasive follicular histology
• Absence of lymph node metastases
• No distant metastases

Unfavorable:

• Age ≥55 years (mortality increases significantly; age > 45 in some systems)
• Male sex
• Tumor size > 4 cm
• Extrathyroidal extension (especially gross ETE)
• Aggressive histology (tall cell, columnar cell, widely invasive follicular)
• Extensive vascular invasion
• Lymph node metastases (especially N1b, > 5 nodes, nodes > 3 cm)
• Distant metastases (M1) - lungs, bones

MACIS Score (Metastases, Age, Completeness of resection, Invasion, Size): Predicts 20-year disease-specific mortality in papillary carcinoma:

• Score less than 6: 99% survival
• Score 6-7: 89% survival
• Score > 8: 56% survival

Recurrence:

• Overall recurrence rate: 10-30% over 10-20 years
• Most recurrences in first 5 years, but late recurrences (> 10 years) occur
• Locoregional recurrence (lymph nodes): 15-20%
• Distant metastases: 5-10%
• Majority of recurrences can be salvaged with further surgery ± RAI

Distant Metastases:

• Lungs most common site (80%) - often respond to RAI ("iodine-avid" if differentiated)
• Bones (20%) - often lytic lesions; follicular > papillary
• Brain, liver (rare)
• Median survival with distant metastases: 5-10 years (much better than most solid organ cancers)
• Older patients, large metastases, RAI-refractory disease have worse outcomes

Medullary Thyroid Carcinoma

Variable Prognosis:

• 10-year overall survival: ~75% [4]
• Better if confined to thyroid; worse with nodal/distant metastases

Prognostic Factors:

• Stage at diagnosis (most important)
• Completeness of surgical resection
• Post-operative calcitonin levels:
  • "Undetectable: Excellent prognosis"
  • "Persistently elevated: Residual disease"
  • "Doubling time less than 6 months: Aggressive disease"
• Hereditary vs sporadic (hereditary often younger, may have better outcomes if detected via screening)

Recurrence:

• 50% have persistent disease after surgery (elevated calcitonin)
• Slowly progressive in many cases

Anaplastic Thyroid Carcinoma

Dismal Prognosis:

• Median survival: 3-5 months [5]
• 1-year survival: less than 20%
• Most die from locoregional disease (airway obstruction, vascular invasion)

Only Favorable Factor:

• Complete surgical resection (very rare, achievable in less than 10%)
• Response to BRAF-targeted therapy (if BRAF V600E positive)

Poorly Differentiated Thyroid Carcinoma

• 5-year survival: 50-70%
• Intermediate between DTC and ATC

---

10. Complications and Sequelae

Disease-Related Complications

Airway Compromise:

• Tracheal compression from large goiter or aggressive cancer
• Tracheal invasion (anaplastic carcinoma)
• Bilateral recurrent laryngeal nerve palsy
• Requires urgent surgical airway (tracheostomy)

Vascular Complications:

• Carotid artery encasement/invasion (advanced cancer)
• Superior vena cava syndrome (retrosternal extension)
• Hemorrhage into tumor (rare)

Skeletal Complications:

• Pathological fractures from bone metastases
• Spinal cord compression (vertebral metastases)

Paraneoplastic Syndromes (Medullary Carcinoma):

• Diarrhea (40% of advanced MTC) - from calcitonin, prostaglandins, VIP
• Cushing syndrome (ectopic ACTH)
• Carcinoid syndrome (serotonin)

Treatment-Related Complications

Post-Thyroidectomy:

• Permanent hypothyroidism: Universal after total thyroidectomy; requires lifelong levothyroxine
• Permanent hypoparathyroidism: 1-5% after total thyroidectomy with central neck dissection
  • "Hypocalcemia symptoms: Perioral tingling, paresthesias, carpopedal spasm (Trousseau sign), tetany, seizures"
  • Requires calcium (1-3 g elemental calcium daily) + calcitriol (0.25-1 mcg daily)
  • Monitor calcium, phosphate, magnesium, vitamin D
• Recurrent laryngeal nerve injury:
  • "Temporary (neuropraxia): 5-10%; recovers over weeks-months"
  • "Permanent: 1-2%"
  • "Unilateral: Breathy, hoarse voice; aspiration risk"
  • "Bilateral: Vocal cords adducted → airway obstruction → emergency tracheostomy"
• Bleeding/hematoma: 1-2%; can cause airway compromise (requires urgent evacuation)
• Wound infection: less than 1%
• Keloid/hypertrophic scar: Cosmetic concern

Post-Radioiodine:

• Sialadenitis/xerostomia: 30% develop salivary gland inflammation and dry mouth
  • Sialagogues (lemon drops), hydration, sialendoscopy if severe
• Lacrimal dysfunction: Dry eyes, epiphora
• Taste changes: Temporary or permanent
• Radiation thyroiditis: Neck pain/swelling in first week (if remnant tissue)
• Second malignancies: Small increased risk with cumulative RAI > 600 mCi (leukemia 0.3%, salivary cancer 2-5%)
• Pulmonary fibrosis: Very rare; with high doses for diffuse lung metastases
• Bone marrow suppression: Transient with high doses

TSH Suppression (Subclinical Hyperthyroidism):

• Atrial fibrillation: 2-3 fold increased risk (particularly > 65 years) [17]
• Osteoporosis/fractures: Reduced BMD, particularly postmenopausal women [18]
• Cardiovascular effects: Increased heart rate, contractility, left ventricular hypertrophy (long-term)
• Neuropsychiatric: Anxiety, tremor, insomnia

---

11. Prevention and Screening

Primary Prevention

Radiation Avoidance:

• Minimize unnecessary medical radiation exposure, particularly in children
• Appropriate shielding during diagnostic imaging

Iodine Sufficiency:

• Adequate dietary iodine reduces risk of follicular carcinoma
• Universal salt iodization programs in endemic goiter areas

Chemoprevention: No proven chemoprevention strategies for sporadic thyroid cancer

Secondary Prevention (Early Detection)

General Population Screening:

• NOT recommended for asymptomatic individuals without risk factors
• High prevalence of incidental thyroid nodules (20-70% on ultrasound) would lead to overdiagnosis and overtreatment of indolent disease
• No mortality benefit demonstrated

High-Risk Screening:

1. Hereditary Medullary Thyroid Carcinoma (MEN2):

• Genetic testing: ALL first-degree relatives of MEN2 patients should undergo RET mutation testing [4]
• If RET mutation identified:
  • "Prophylactic thyroidectomy recommendations based on mutation codon:"
    • Highest risk (MEN2B, codon 918): Thyroidectomy in first year of life
    • High risk (codon 634): Thyroidectomy before age 5 years
    • Moderate risk (other codons): Consider based on calcitonin levels and family history
  • Annual screening for pheochromocytoma (from age 8-10) with plasma/urine metanephrines
  • Calcium/PTH screening for hyperparathyroidism (MEN2A)

2. Radiation Exposure History:

• External beam radiation to head/neck in childhood:
  • Neck palpation annually
  • Consider ultrasound surveillance (controversial; some recommend every 1-5 years)
• Dose-dependent risk; latency period 5-40 years (peak 15-25 years)

3. Familial Non-Medullary Thyroid Cancer:

• First-degree relatives have 3-5 fold increased risk
• No consensus screening guidelines
• Consider ultrasound surveillance if ≥2 affected family members

---

12. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. TSH Suppression in DTC:

• McGriff et al. (2002): Retrospective study showing recurrence rates 14% with TSH less than 0.05 vs 20% with TSH 0.05-0.5 vs 26% with TSH > 0.5 [16]
• Multiple meta-analyses confirm benefit in high-risk disease
• Ongoing debate about degree and duration in low-risk patients due to cardiovascular/bone risks [17,18]

2. ATA Risk Stratification:

• Tuttle et al. (2010): Introduced dynamic risk stratification concept - response to therapy predicts outcomes better than initial staging [3]
• Excellent response → very low recurrence (less than 1-2%)
• Allows de-escalation of surveillance in low-risk responders

3. Active Surveillance for Papillary Microcarcinoma:

• Japanese studies (Ito et al., Miyauchi et al.): > 1,200 patients with papillary microcarcinoma (less than 1 cm) observed without surgery [20]
  • Only 8% showed size increase ≥3 mm at 10 years
  • less than 1% developed lymph node metastases
  • Surgery can be safely deferred in selected low-risk patients
• Emerging strategy in Western guidelines for unifocal, low-risk microcarcinomas without concerning features

4. BRAF Mutation Prognostic Value:

• Xing et al. (2013): Large meta-analysis showing BRAF V600E associated with increased recurrence, extrathyroidal extension, lymph node metastases, and mortality [11]
• Debate continues about whether BRAF status should alter initial surgical approach

5. Selective RET Inhibitors in MTC:

• LIBRETTO-001 trial (selpercatinib): 69% objective response rate in RET-mutant MTC [21]
• ARROW trial (pralsetinib): 60% ORR in RET-mutant MTC [22]
• Superior efficacy and tolerability compared to multi-kinase inhibitors

6. BRAF/MEK Inhibition in Anaplastic Cancer:

• Subbiah et al. (2018): Dabrafenib + trametinib in BRAF V600E ATC showed 69% response rate - unprecedented in ATC [19]
• FDA approved 2018 for BRAF V600E-mutant ATC

---

13. Special Populations

Pregnancy

Thyroid Cancer Discovered During Pregnancy:

• FNA can be safely performed if indicated
• Timing of surgery:
  • "If rapidly growing or aggressive features: Surgery in second trimester (safest for fetus)"
  • "If stable: Defer surgery until post-partum (most common approach for low-risk DTC)"
• TSH suppression: Levothyroxine dose adjusted to maintain TSH in pregnancy-specific ranges (lower than non-pregnant)
• Radioiodine: Absolutely contraindicated in pregnancy and breastfeeding (causes fetal thyroid ablation)

Known Thyroid Cancer During Pregnancy:

• Continue levothyroxine; adjust dose based on TSH (increased requirement in pregnancy)
• Monitor with neck ultrasound and Tg if already on surveillance
• Defer RAI until 6-12 months post-partum and after cessation of breastfeeding

Pediatric Thyroid Cancer

• More likely to present with advanced disease (lymph node metastases in 60-80%, lung metastases in 20%)
• Paradoxically, excellent prognosis despite advanced stage (> 95% long-term survival)
• Treatment: Total thyroidectomy + neck dissection if nodes involved; RAI commonly used
• Consideration of growth/development when planning TSH suppression
• Higher cure rates with RAI than adults (better iodine uptake)

Elderly Patients (> 70 years)

• Higher proportion of aggressive histologies (tall cell variant, poorly differentiated, anaplastic)
• Worse prognosis (age is strongest prognostic factor)
• Surgical risk higher (comorbidities)
• TSH suppression risks (atrial fibrillation, osteoporosis) must be carefully weighed
• Consider less aggressive TSH targets in low-risk disease

---

14. Patient and Layperson Explanation

What is Thyroid Cancer?

Thyroid cancer is a growth of abnormal cells in the thyroid gland, a butterfly-shaped organ in the front of your neck that produces hormones controlling your metabolism. Most thyroid cancers grow slowly and can be successfully treated.

Is it Curable?

Yes, highly curable in the vast majority of cases. More than 90% of people diagnosed with the most common types (papillary and follicular thyroid cancer) are cured and go on to live normal lifespans. Even people with spread to lymph nodes usually do very well. Thyroid cancer is sometimes called the "good cancer" (although no cancer is truly good), reflecting its generally excellent prognosis.

How is it Treated?

Surgery: Usually, we remove the entire thyroid gland (total thyroidectomy) or half of it (hemithyroidectomy) depending on the size and type of cancer. If lymph nodes are involved, these are also removed. Surgery is usually curative for early-stage disease.

Radioactive Iodine: After surgery for larger or higher-risk cancers, you might swallow a radioactive iodine pill. Because thyroid cells (including cancer cells) naturally absorb iodine, the radioactivity concentrates in any remaining thyroid tissue and kills it. You'll need to stay isolated for a few days while you're radioactive.

Thyroid Hormone Tablets: After your thyroid is removed, you'll take levothyroxine tablets every morning for the rest of your life to replace the hormone your thyroid used to make. We often give a slightly higher dose than normal to suppress TSH (a hormone that can stimulate cancer cells), which may help prevent the cancer from coming back.

Will I Need Lifelong Follow-Up?

Yes. Even though thyroid cancer is highly curable, it can occasionally come back years or even decades later. You'll have regular blood tests (thyroglobulin - a tumor marker) and neck ultrasounds to check for recurrence. The good news is that even if it does come back, it can usually be treated successfully.

What About My Daily Life?

Most thyroid cancer survivors lead completely normal lives. You'll take a daily thyroid hormone tablet, have regular check-ups, and need to avoid becoming pregnant for 6-12 months after radioactive iodine treatment. Otherwise, you can work, exercise, and do everything you did before diagnosis.

What if I Have a Family?

Most thyroid cancers are not hereditary - they don't run in families. However, one type (medullary thyroid cancer) can be hereditary in about 25% of cases. If you have this type, your doctor will offer genetic testing to see if family members should be screened.

---

15. Examination Focus

Common MRCP/Postgraduate Exam Questions

1. "A 35-year-old woman presents with a 2 cm thyroid nodule. FNA returns Thy3f (follicular neoplasm). What is your management?"

Model Answer: "Thy3f indicates a follicular lesion of uncertain malignant potential. Cytology cannot distinguish benign follicular adenoma from follicular carcinoma, as the diagnosis of carcinoma requires demonstration of capsular or vascular invasion on histological examination. Therefore, I would recommend diagnostic hemithyroidectomy with definitive histology. If the histology confirms follicular carcinoma with vascular invasion or aggressive features, completion thyroidectomy can be performed. Minimally invasive follicular carcinoma less than 2 cm may not require completion."

2. "What is the 'follicular dilemma'?"

Model Answer: "The 'follicular dilemma' refers to the inability to distinguish follicular adenoma from follicular carcinoma on fine needle aspiration cytology. Both appear as follicular cells on FNA (Thy3f). The defining feature of follicular carcinoma is capsular or vascular invasion, which can only be assessed on histological examination of the excised specimen. Therefore, diagnostic lobectomy is required for all Thy3f lesions to establish the diagnosis."

3. "A patient develops perioral tingling and carpopedal spasm 24 hours post-total thyroidectomy. What is the most likely diagnosis and immediate management?"

Model Answer: "The most likely diagnosis is hypocalcemia due to hypoparathyroidism from inadvertent parathyroid gland removal or devascularization during surgery. Immediate management includes:

• Urgent serum calcium and phosphate measurement (expect low calcium, high phosphate)
• Check for Chvostek and Trousseau signs
• IV calcium gluconate 10-20 mL of 10% solution if severe or symptomatic (risk of tetany, laryngospasm, seizures)
• Start oral calcium carbonate (1-3 g elemental calcium daily) and calcitriol (0.25-0.5 mcg daily)
• Monitor calcium closely; may be temporary (transient hypoparathyroidism in 20-30%) or permanent (1-5%)"

4. "What blood test is used to monitor for recurrence of differentiated thyroid cancer post-total thyroidectomy?"

Model Answer: "Thyroglobulin (Tg) is the tumor marker of choice. Thyroglobulin is produced by thyroid follicular cells. After total thyroidectomy and radioiodine ablation, Tg should be undetectable (less than 1 ng/mL). Rising or persistently elevated Tg indicates residual or recurrent disease. Tg must be measured alongside anti-thyroglobulin antibodies, as these interfere with the assay in 15-20% of patients and can cause falsely low results. Stimulated Tg (after TSH elevation via rhTSH or withdrawal) is more sensitive than suppressed Tg."

5. "A 70-year-old man presents with a rapidly enlarging hard neck mass over 4 weeks, associated with hoarseness and stridor. What is the most likely diagnosis and prognosis?"

Model Answer: "The presentation of a rapidly enlarging, hard, fixed neck mass with compressive symptoms (hoarseness from recurrent laryngeal nerve invasion, stridor from tracheal compression) in an elderly patient is highly suspicious for anaplastic thyroid carcinoma. This is an undifferentiated, highly aggressive malignancy with a dismal prognosis - median survival 3-5 months. Urgent airway management (often requiring tracheostomy) is a priority. Core biopsy confirms diagnosis. Treatment is usually palliative multimodal therapy (EBRT, chemotherapy). BRAF-targeted therapy (dabrafenib + trametinib) may be considered if BRAF V600E mutation is present."

6. "What is the role of radioactive iodine in medullary thyroid carcinoma?"

Model Answer: "There is NO role for radioactive iodine in medullary thyroid carcinoma. MTC arises from parafollicular C-cells, which do not express the sodium-iodide symporter and therefore do not concentrate radioiodine. The primary treatment for MTC is total thyroidectomy with central neck dissection. Post-operative monitoring uses serum calcitonin and CEA as tumor markers. Systemic therapy for metastatic disease includes tyrosine kinase inhibitors targeting RET (selpercatinib, pralsetinib, vandetanib, cabozantinib)."

7. "A patient with MEN2A is diagnosed. What pre-operative investigation is essential before thyroidectomy and why?"

Model Answer: "Screening for pheochromocytoma is essential. MEN2A is associated with:

• Medullary thyroid carcinoma (nearly 100%)
• Pheochromocytoma (50%)
• Primary hyperparathyroidism (20-30%)

Undiagnosed pheochromocytoma poses a significant risk of hypertensive crisis during surgery, which can be fatal. Screen with 24-hour urinary metanephrines or plasma metanephrines. If pheochromocytoma is present, it must be treated FIRST with alpha-blockade (phenoxybenzamine) followed by adrenalectomy, before proceeding with thyroidectomy. Also check serum calcium and PTH for hyperparathyroidism."

8. "What histological features are pathognomonic for papillary thyroid carcinoma?"

Model Answer: "The pathognomonic features are:

• 'Orphan Annie Eye' nuclei: Ground-glass, optically clear nuclei due to chromatin margination
• Nuclear grooves: Longitudinal grooves in nuclei
• Nuclear pseudoinclusions: Invaginations of cytoplasm into nucleus
• Psammoma bodies: Concentric laminated calcific structures The diagnosis is based on nuclear features rather than papillary architecture (as follicular variant of PTC lacks papillae)."

Viva Points

Opening Statement for Papillary Thyroid Carcinoma: "Papillary thyroid carcinoma is a well-differentiated malignancy of thyroid follicular epithelial cells, accounting for 80-85% of thyroid cancers. It predominantly affects young to middle-aged women with a female:male ratio of 3:1. It is characterized by excellent prognosis with 10-year survival exceeding 90%. The hallmark is spread via lymphatic routes to cervical lymph nodes, rather than hematogenous spread. Molecular drivers include BRAF V600E mutation in 40-45% and RET/PTC rearrangements in 10-20%, particularly radiation-induced cases."

Key Facts to Mention:

• Classification: WHO 2017 recognizes multiple variants (classic, follicular variant, tall cell variant - more aggressive)
• Diagnosis: U-grading on ultrasound, Thy-grading on FNA cytology
• Treatment: Risk-stratified approach per ATA 2015 guidelines
  • "Low risk: May consider lobectomy for tumors less than 2 cm"
  • "Higher risk: Total thyroidectomy, consider RAI, TSH suppression"
• Surveillance: Thyroglobulin monitoring post-thyroidectomy
• Prognosis: Excellent; recurrence in 10-30% but usually salvageable

Opening Statement for Medullary Thyroid Carcinoma: "Medullary thyroid carcinoma is a neuroendocrine tumor arising from parafollicular C-cells, accounting for 3-5% of thyroid malignancies. Unlike differentiated cancers, it secretes calcitonin (tumor marker) and is associated with hereditary syndromes in 25-30% of cases via germline RET proto-oncogene mutations (MEN2A, MEN2B, FMTC). It does not concentrate radioiodine. Treatment is total thyroidectomy with prophylactic central neck dissection due to high rates of microscopic nodal disease. Pre-operative screening for pheochromocytoma is mandatory to prevent intraoperative crisis."

Common Mistakes

❌ Mistakes that fail candidates:

1. Stating that FNA can diagnose follicular carcinoma

   • Correct: Only histology showing capsular/vascular invasion can diagnose follicular carcinoma

2. Using radioiodine for medullary thyroid carcinoma

   • Correct: MTC does not concentrate iodine; calcitonin monitoring + targeted therapy (RET inhibitors)

3. Forgetting to screen for pheochromocytoma before MEN2 thyroidectomy

   • Correct: Always screen; treat pheo FIRST to avoid hypertensive crisis

4. Recommending TSH suppression less than 0.1 for ALL thyroid cancer patients

   • Correct: Risk-stratified targets (low-risk can have TSH 0.5-2.0); balance recurrence risk vs cardiovascular/bone risks

5. Not recognizing anaplastic thyroid cancer as a surgical emergency

   • Correct: Airway compromise common; tracheostomy often required; extremely poor prognosis

6. Using thyroglobulin for initial diagnosis

   • Correct: Tg is elevated in many benign conditions; used for POST-OPERATIVE surveillance only

---

16. References

Primary Sources

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763

2. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12(11):646-653. doi:10.1038/nrendo.2016.110

3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020

4. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. doi:10.1089/thy.2014.0335

5. Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644-660. doi:10.1038/nrendo.2017.76

6. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-1779. doi:10.2217/fon.10.127

7. Knobel M, Medeiros-Neto G. Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51(5):701-712.

8. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259-277.

9. Cardis E, Kesminiene A, Ivanov V, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005;97(10):724-732. doi:10.1093/jnci/dji129

10. Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women. Int J Cancer. 2011;129(1):160-172. doi:10.1002/ijc.25628

11. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501. doi:10.1001/jama.2013.3190

12. Santoro M, Carlomagno F. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013;5(12):a009233. doi:10.1101/cshperspect.a009233

13. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3):809-814. doi:10.1210/jc.2007-2215

14. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122. doi:10.1111/cen.12515

15. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144-1152. doi:10.1089/thy.2012.0043

16. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34(7-8):554-564.

17. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20(2):135-146. doi:10.1089/thy.2009.0311

18. Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin suppression on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16(6):583-591. doi:10.1089/thy.2006.16.583

19. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7-13. doi:10.1200/JCO.2017.73.6785

20. Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27-34. doi:10.1089/thy.2013.0367

21. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835. doi:10.1056/NEJMoa2005651

22. Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491-501. doi:10.1016/S2213-8587(21)00120-0

23. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(11):4158-4163. doi:10.1210/jc.2008-0896

24. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation. J Clin Endocrinol Metab. 2010;95(5):2038-2046. doi:10.1210/jc.2009-2572

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.